Kite Pharma Inc. (NASDAQ:KITE)’s share price traded down 1.1% during trading on Tuesday . The company traded as low as $60.30 and last traded at $60.58, with a volume of 200,551 shares traded. The stock had previously closed at $61.23.

A number of equities research analysts have issued reports on the company. Jefferies Group reiterated a “buy” rating and issued a $72.00 target price on shares of Kite Pharma in a research note on Saturday, July 9th. Vetr upgraded Kite Pharma from a “sell” rating to a “buy” rating and set a $58.58 target price on the stock in a research note on Tuesday, August 2nd. Mizuho reiterated a “hold” rating and issued a $80.00 target price on shares of Kite Pharma in a research note on Friday, July 8th. Stifel Nicolaus raised their target price on Kite Pharma from $63.00 to $74.00 and gave the company a “buy” rating in a research note on Wednesday, July 13th. Finally, FBR & Co reiterated a “buy” rating on shares of Kite Pharma in a research note on Monday, May 2nd. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $73.53.

The company’s market cap is $2.85 billion. The firm has a 50-day moving average price of $54.88 and a 200 day moving average price of $49.90.

Kite Pharma (NASDAQ:KITE) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.30. During the same quarter last year, the company earned ($0.26) earnings per share. The company earned $4.80 million during the quarter, compared to the consensus estimate of $4.86 million. The business’s revenue was up 9.1% on a year-over-year basis. Equities analysts expect that Kite Pharma Inc. will post ($5.83) earnings per share for the current fiscal year.

In other Kite Pharma news, SVP Jeffrey Wiezorek sold 3,000 shares of the company’s stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $50.65, for a total value of $151,950.00. Following the sale, the senior vice president now directly owns 16,367 shares in the company, valued at $828,988.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Cynthia M. Butitta sold 20,000 shares of the company’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $50.71, for a total value of $1,014,200.00. Following the completion of the sale, the chief operating officer now owns 105,401 shares in the company, valued at $5,344,884.71. The disclosure for this sale can be found here.

Several hedge funds have made changes to their positions in KITE. Dimensional Fund Advisors LP acquired a new stake in shares of Kite Pharma during the fourth quarter valued at approximately $2,088,000. Mutual of America Capital Management LLC boosted its stake in shares of Kite Pharma by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock valued at $1,007,000 after buying an additional 95 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Kite Pharma by 58.8% in the fourth quarter. California Public Employees Retirement System now owns 51,300 shares of the biopharmaceutical company’s stock valued at $3,161,000 after buying an additional 19,000 shares during the last quarter.

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.